Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 3/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | GPR183 | P32249 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3797551 | 1.00 | ALDH1A1 (0.49) | ALDH1A1HPGDTSHRSLC18A3GRM5 | |
| SCHEMBL2456130 | 0.87 | GRM5 (0.46) | ALDH1A1HPGDTSHRGRM5MTNR1A | |
| SCHEMBL3795877 | 0.85 | MTNR1A (0.51) | ALDH1A1HPGDTSHRSLC18A3GRM5 | |
| SCHEMBL3802170 | 0.84 | ALDH1A1 (0.47) | ALDH1A1HPGDTSHRGRM5MTNR1A | |
| SCHEMBL3802173 | 0.84 | ALDH1A1 (0.47) | ALDH1A1HPGDTSHRGRM5MTNR1A | |
| SCHEMBL3796879 | 0.83 | ALDH1A1 (0.68) | ALDH1A1HPGDGRM5MTNR1AMTNR1B | |
| SCHEMBL3796921 | 0.82 | HPGDS (0.54) | ALDH1A1HPGDTSHRGRM5MTNR1A | |
| SCHEMBL3796922 | 0.82 | HPGDS (0.54) | ALDH1A1HPGDTSHRGRM5MTNR1A | |
| SCHEMBL3793522 | 0.82 | GRM5 (0.57) | ALDH1A1HPGDTSHRGRM5MTNR1A | |
| SCHEMBL3793624 | 0.81 | GRM5 (0.56) | ALDH1A1TSHRGRM5MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709478-B2 | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| EP-1362027-B1 | ACYLATED 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYL AMINES AND THEIR USE AS PHARMACEUTICAL | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-05-21 | — | — | EP | disclosed |
| US-20040225013-A1 | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-11 | — | — | US | disclosed |
| US-6759412-B2 | FOR PRODUCING DRUGS USED FOR THERAPY OF CARDIOVASCULAR DISEASES, STABLE OR UNSTABLE ANGINA PECTORIS, CORONARY HEART DISEASE, PRINZMETAL ANGINA, ACUTE CORONARY SYNDROME, HEART FAILURE, MYOCARDIAL INFARCTION, STROKE, THROMBOSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-06 | — | — | US | disclosed |
| US-20030008915-A1 | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008915-A1 | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents | VEGFA, NR1H2, EDNRA | ALDH1A1 343/4885HPGD 929/4885TSHR 871/4885 |
| US-20040225013-A1 | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents | VEGFA, NR1H2, EDNRA | ALDH1A1 343/4885HPGD 929/4885TSHR 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.